Intravenous immunoglobulins: evolution of commercial IVIG preparations.
about
Entecavir-Associated Thrombocytopenia in a Decompensated Cirrhotic Patient: A Case Report and Literature ReviewThe Production Processes and Biological Effects of Intravenous ImmunoglobulinIntravenous immunoglobulin as clinical immune-modulating therapy.II Brazilian Consensus on the use of human immunoglobulin in patients with primary immunodeficiencies.Workshop on use of intravenous immunoglobulin in hand, foot and mouth disease in Southeast Asia.Comparison of Fc N-Glycosylation of Pharmaceutical Products of Intravenous Immunoglobulin GIntravenous immune globulin and thromboembolic adverse events: A systematic review and meta-analysis of RCTs.Immunoglobulin: production, mechanisms of action and formulations.Intravenous immunoglobulin therapy for autoimmune diseases.IVIG Effects on Erythrocyte Sedimentation Rate in Children.Pathogen Safety of a New Intravenous Immune Globulin 10% Liquid.Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again.Intravenous immunoglobulin in pediatrics: A review.Intravenous immunoglobulin in the treatment of neurologic disorders.Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient?Immunotherapeutic Biologic Agents in Autoimmune and Autoinflammatory Diseases.IVIG-Associated Maternal Pancytopenia during Treatment for Neonatal Alloimmune ThrombocytopeniaModeling primary immunodeficiency disease epidemiology and its treatment to estimate latent therapeutic demand for immunoglobulin.New insights in the use of immunoglobulins for the management of immune deficiency (PID) patients.Updated treatment strategies for intestinal Behçet's disease.HPLC fingerprinting approach for raw material assessment and unit operation tracking for IVIG production from Cohn I+II+III fraction.Dedicated removal of immunoglobulin (Ig)A, IgM, and Factor (F)XI/activated FXI from human plasma IgG.
P2860
Q26750766-095258F8-12C4-4CAD-B07B-BB70F7A112E7Q26752540-AC7E988E-20FE-48D3-854D-418C46631F93Q33420267-E72D0750-6219-4049-9C7A-2574BD46DB08Q33692418-647BE16E-E2B4-4702-83EF-C2502D055F50Q34844126-70BB0A34-43D8-404B-A5F8-51D9BB91AC72Q35803387-74BE16CB-7EDB-483D-8B56-E511D1D69449Q35955607-60A9EAE9-2174-4061-8A16-91E881DE889CQ36153609-4F96EC37-05A3-42B6-BB13-AB2C50D02972Q37573529-E3FBD026-8981-41E9-9227-57A7792576FFQ37615167-C71D221C-6C7D-4404-910F-C91B323C15F9Q37737558-FDD49462-519D-428D-A884-E630F2D33C96Q38029244-7B737062-656B-48A7-8AE5-D5193D32B004Q38266015-CEE615E4-D41E-404A-B027-739D5796641BQ38495457-4FC254B4-4F06-49EA-882C-5A7F8998DA2AQ38569717-6C15DA71-B889-460A-A524-3B6A21061D39Q38635412-042D14D0-A34B-42F0-BB50-23E6C07B1EF9Q42367705-6FCD6B01-A793-443C-AA80-DF96B3A1E81DQ44871560-266F953E-2700-45B2-9AAB-7916FBBF026FQ45012826-916A6ECB-115D-4B14-AAE3-F331F81393D3Q47327588-F2793C53-CFD2-401E-B836-E3F661DA02CDQ48095460-6B28A132-30A0-4759-BF53-F3C4BD3A2165Q50967516-2BF2402B-652F-45BF-B692-2AF1E42B8331
P2860
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
description
2008 nî lūn-bûn
@nan
2008 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
@ast
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
@en
type
label
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
@ast
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
@en
prefLabel
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
@ast
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
@en
P1476
Intravenous immunoglobulins: evolution of commercial IVIG preparations.
@en
P2093
John A Hooper
P304
765-78, viii
P356
10.1016/J.IAC.2008.06.002
P577
2008-11-01T00:00:00Z